Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo
- PMID: 12150648
- DOI: 10.1001/archpsyc.59.8.723
Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo
Abstract
Background: Chronic forms of depression are associated with significant functional and psychosocial impairments. To date, no study has measured psychosocial functioning in this population during long-term maintenance antidepressant treatment or following the double-blind discontinuation of treatment.
Methods: Patients with chronic major or double depression completed 12 weeks of short-term treatment followed by 16 weeks of continuation treatment with sertraline hydrochloride. Responders at the end of the continuation phase were randomized, double-blind, to 18 months of maintenance therapy with either sertraline (n = 77) or placebo (n = 84). Multiple domains of psychosocial functioning were assessed during double-blind therapy.
Results: Substantial worsening in psychosocial function measures occurred in patients taking placebo compared with sertraline during maintenance. Patients with reemergence of depression lost psychosocial gains regardless of treatment. In the subsample of patients who remained in remission throughout maintenance, most of the observed improvement in psychosocial functioning occurred during short-term treatment. By maintenance end point, normalization of functioning was achieved by 58% to 84% of remitters, depending on the outcome measure used.
Conclusions: These results indicate that long-term treatment of chronic forms of depression can result in sustained psychosocial benefits. Discontinuation of treatment results in frequent reemergence of symptoms and loss of psychosocial gains. Long-term treatment resulted in only modest further improvement of psychosocial measures over that achieved in the short-term phase.
Comment in
-
18-month maintenance treatment with sertraline may have sustained psychosocial benefits in chronic depression.Evid Based Ment Health. 2003 May;6(2):49. doi: 10.1136/ebmh.6.2.49. Evid Based Ment Health. 2003. PMID: 12719356 No abstract available.
Similar articles
-
Novel Augmentation Strategies in Major Depression.Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review.
-
Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment.J Clin Psychiatry. 2002 Jan;63(1):59-65. doi: 10.4088/jcp.v63n0112. J Clin Psychiatry. 2002. PMID: 11838628 Clinical Trial.
-
Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline.J Clin Psychiatry. 2001 Jan;62(1):24-9. doi: 10.4088/jcp.v62n0106. J Clin Psychiatry. 2001. PMID: 11235924 Clinical Trial.
-
The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine.J Clin Psychiatry. 1998 Nov;59(11):608-19. doi: 10.4088/jcp.v59n1108. J Clin Psychiatry. 1998. PMID: 9862607 Clinical Trial.
-
Efficacy in long-term treatment of depression.J Clin Psychiatry. 1996;57 Suppl 2:24-30. J Clin Psychiatry. 1996. PMID: 8626360 Review.
Cited by
-
What does "staying well" after depression mean? Chronic low grade symptomatology after treatment for depression is common.J Affect Disord. 2022 Nov 15;317:228-235. doi: 10.1016/j.jad.2022.08.075. Epub 2022 Aug 24. J Affect Disord. 2022. PMID: 36029878 Free PMC article.
-
Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults.Cochrane Database Syst Rev. 2021 Apr 15;4(4):CD013495. doi: 10.1002/14651858.CD013495.pub2. Cochrane Database Syst Rev. 2021. PMID: 33886130 Free PMC article.
-
Health-related quality of life in remitted psychotic depression✰.J Affect Disord. 2019 Sep 1;256:373-379. doi: 10.1016/j.jad.2019.05.068. Epub 2019 May 28. J Affect Disord. 2019. PMID: 31207561 Free PMC article.
-
Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults.Cochrane Database Syst Rev. 2019 May 20;5(5):CD012855. doi: 10.1002/14651858.CD012855.pub2. Cochrane Database Syst Rev. 2019. PMID: 31106850 Free PMC article.
-
ECT Has Greater Efficacy Than Fluoxetine in Alleviating the Burden of Illness for Patients with Major Depressive Disorder: A Taiwanese Pooled Analysis.Int J Neuropsychopharmacol. 2018 Jan 1;21(1):63-72. doi: 10.1093/ijnp/pyx114. Int J Neuropsychopharmacol. 2018. PMID: 29228200 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical